Daily ideas

Colgate-Palmolive grew Q2 2026 net sales 4.9% to $5.36 billion as gross margin rose 140 bps to 61.5%; Q3 tests whether North American volume, down 3.9%, recovers.

Garmin grew Q2 2026 revenue 11% to $2.02 billion at a 62.4% gross margin; Q3 tests whether Fitness growth can outrun rising memory chip costs.

India's 2026-27 ethanol tender excludes cane routes, shifting about 2.56 billion litres to grain and possibly raising maize feed costs for Venky's.

Republic Services grew Q2 2026 revenue 4.6% to $4.43 billion on 4.0% average yield as volume fell 1.9%; Q3 results test whether pricing still covers volume and margin holds flat.

Deutsche Bank's core divisions grew Q2 2026 revenue 9.6% to €8.4 billion, led by a 19% Investment Bank gain; Q3 tests whether deposit and fee income can offset cooler trading.

TE Connectivity posted record Q3 FY2026 sales of $5.16 billion, up 14%, with orders up 27%; Q4 results test whether AI orders become revenue as metal costs rise.

Teradyne's Q2 2026 revenue doubled to $1.33 billion at a 33.7% non-GAAP operating margin; Q3 tests how far SoC test sales fall and whether memory fills the gap.

Genuine Parts grew Q2 sales 6.0% to $6.54 billion as adjusted EBITDA margin slipped to 8.7%; Q3 tests whether pricing outruns cost inflation and NAPA holds 2% comps.

Equifax grew Q2 2026 revenue 11% to $1.70B, but only about 7% excluding FICO royalties; Q3 tests whether government verification stops falling and EWS regains 8% growth.

Regeneron's Q2 2026 revenue rose 17% to $4.29 billion, half from Sanofi's Dupixent profit share; Q3 tests whether a $253 million repaid deduction lifts operating income.

Aon's Q2 2026 revenue rose 2% to $4.246 billion on 5% organic growth and a 28.9% adjusted margin; Q3 tests whether free cash flow can catch up before the $17 billion USI deal closes.

Vertex grew Q2 2026 revenue 12% to $3.33B as CF rose 10.6% and royalties fell to 8.44%; Q3 tests whether the ALYFTREK switch keeps CF growth above 5%.

Quest Diagnostics grew Q2 2026 revenue 10.2% to $3.04 billion with core volume up 4.1% ex-partnerships; Q3 tests whether that holds as partner margin dilution narrows.

Truist, M&T and Regions sold, reclassified or hedged long-dated bonds in Q3 2026 as a Basel III re-proposal moves AFS losses toward core capital.

MSCI proposes moving Indonesia to Standalone status, which could force fund selling of Indofood and squeeze First Pacific's quoted-price NAV and dollar earnings.

Motorola Solutions' Q2 2026 sales rose 13% to $3.13 billion with a record $15.6 billion backlog; Q3 tests whether organic LMR shipments can carry the guided Q4 ramp.

Boston Scientific grew Q2 2026 sales 7.5% to $5.44 billion before an August cyberattack halted shipping; Q3 results show how much lost revenue returns in Q4.

Enterprise Products earned $0.84 a unit in Q2 2026, up 28%, with record $2.31B distributable cash flow; Q3 tests how much Middle East spread gains fade as capex rises.

Verisign's Q2 2026 revenue rose 6.0% to $434.6 million as its .com/.net base grew 5.1%; Q3 tests whether record new registrations renew and carry revenue to guidance.